These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

510 related articles for article (PubMed ID: 23845174)

  • 1. Everolimus in tuberous sclerosis patients with intractable epilepsy: a treatment option?
    Wiegand G; May TW; Ostertag P; Boor R; Stephani U; Franz DN
    Eur J Paediatr Neurol; 2013 Nov; 17(6):631-8. PubMed ID: 23845174
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Everolimus treatment of refractory epilepsy in tuberous sclerosis complex.
    Krueger DA; Wilfong AA; Holland-Bouley K; Anderson AE; Agricola K; Tudor C; Mays M; Lopez CM; Kim MO; Franz DN
    Ann Neurol; 2013 Nov; 74(5):679-87. PubMed ID: 23798472
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term effect of everolimus on epilepsy and growth in children under 3 years of age treated for subependymal giant cell astrocytoma associated with tuberous sclerosis complex.
    Kotulska K; Chmielewski D; Borkowska J; Jurkiewicz E; Kuczyński D; Kmieć T; Łojszczyk B; Dunin-Wąsowicz D; Jóźwiak S
    Eur J Paediatr Neurol; 2013 Sep; 17(5):479-85. PubMed ID: 23567018
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mammalian target of rapamycin inhibitors for intractable epilepsy and subependymal giant cell astrocytomas in tuberous sclerosis complex.
    Cardamone M; Flanagan D; Mowat D; Kennedy SE; Chopra M; Lawson JA
    J Pediatr; 2014 May; 164(5):1195-200. PubMed ID: 24518170
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Everolimus: an mTOR inhibitor for the treatment of tuberous sclerosis.
    Franz DN
    Expert Rev Anticancer Ther; 2011 Aug; 11(8):1181-92. PubMed ID: 21916571
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanistic target of rapamycin (mTOR) in tuberous sclerosis complex-associated epilepsy.
    Curatolo P
    Pediatr Neurol; 2015 Mar; 52(3):281-9. PubMed ID: 25591831
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differentiating the mTOR inhibitors everolimus and sirolimus in the treatment of tuberous sclerosis complex.
    MacKeigan JP; Krueger DA
    Neuro Oncol; 2015 Dec; 17(12):1550-9. PubMed ID: 26289591
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of Everolimus in children with TSC - associated epilepsy - Pilot data from an open single-center prospective study.
    Samueli S; Abraham K; Dressler A; Gröppel G; Mühlebner-Fahrngruber A; Scholl T; Kasprian G; Laccone F; Feucht M
    Orphanet J Rare Dis; 2016 Nov; 11(1):145. PubMed ID: 27809914
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of mTOR inhibitor treatment in patients with tuberous sclerosis complex under 2 years of age - a multicenter retrospective study.
    Saffari A; Brösse I; Wiemer-Kruel A; Wilken B; Kreuzaler P; Hahn A; Bernhard MK; van Tilburg CM; Hoffmann GF; Gorenflo M; Hethey S; Kaiser O; Kölker S; Wagner R; Witt O; Merkenschlager A; Möckel A; Roser T; Schlump JU; Serfling A; Spiegler J; Milde T; Ziegler A; Syrbe S
    Orphanet J Rare Dis; 2019 May; 14(1):96. PubMed ID: 31053163
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial.
    Franz DN; Belousova E; Sparagana S; Bebin EM; Frost M; Kuperman R; Witt O; Kohrman MH; Flamini JR; Wu JY; Curatolo P; de Vries PJ; Whittemore VH; Thiele EA; Ford JP; Shah G; Cauwel H; Lebwohl D; Sahmoud T; Jozwiak S
    Lancet; 2013 Jan; 381(9861):125-32. PubMed ID: 23158522
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Everolimus for epilepsy and autism spectrum disorder in tuberous sclerosis complex: EXIST-3 substudy in Japan.
    Mizuguchi M; Ikeda H; Kagitani-Shimono K; Yoshinaga H; Suzuki Y; Aoki M; Endo M; Yonemura M; Kubota M
    Brain Dev; 2019 Jan; 41(1):1-10. PubMed ID: 30060984
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic pathogenesis of the epileptogenic lesions in Tuberous Sclerosis Complex: Therapeutic targeting of the mTOR pathway.
    Moavero R; Mühlebner A; Luinenburg MJ; Craiu D; Aronica E; Curatolo P
    Epilepsy Behav; 2022 Jun; 131(Pt B):107713. PubMed ID: 33431351
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The Efficacy of Everolimus for Refractory Seizures in Childhood Onset Epilepsy with Tuberous Sclerosis Complex].
    Okanishi T; Fujimoto A; Nishimura M; Baba S; Itamura S; Okanari K; Enoki H
    Brain Nerve; 2019 Jun; 71(6):611-616. PubMed ID: 31171758
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nursing implications for the lifelong management of tuberous sclerosis complex.
    Agricola K; Tudor C; Krueger D; Franz DN
    J Neurosci Nurs; 2013 Aug; 45(4):226-42. PubMed ID: 23812052
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factors affecting response to everolimus therapy for subependymal giant cell astrocytomas associated with tuberous sclerosis.
    Trelinska J; Dachowska I; Kotulska K; Baranska D; Fendler W; Jozwiak S; Mlynarski W
    Pediatr Blood Cancer; 2015 Apr; 62(4):616-21. PubMed ID: 25557360
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Efficacy and safety of rapamycin in treatment of children with epilepsy complicated with tuberous sclerosis].
    Zou L; Liu Y; Pang L; Ju J; Shi Z; Zhang J; Chen X; Su X; Hu L; Shi X; Yang X
    Zhonghua Er Ke Za Zhi; 2014 Nov; 52(11):812-6. PubMed ID: 25582464
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is mTOR inhibition a systemic treatment for tuberous sclerosis?
    Moavero R; Coniglio A; Garaci F; Curatolo P
    Ital J Pediatr; 2013 Sep; 39():57. PubMed ID: 24044547
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Everolimus as adjunctive therapy for tuberous sclerosis complex-associated partial-onset seizures.
    Lechuga L; Franz DN
    Expert Rev Neurother; 2019 Oct; 19(10):913-925. PubMed ID: 31335226
    [No Abstract]   [Full Text] [Related]  

  • 19. Epileptic spasms in tuberous sclerosis complex.
    Hsieh DT; Jennesson MM; Thiele EA
    Epilepsy Res; 2013 Sep; 106(1-2):200-10. PubMed ID: 23796861
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term treatment of epilepsy with everolimus in tuberous sclerosis.
    Krueger DA; Wilfong AA; Mays M; Talley CM; Agricola K; Tudor C; Capal J; Holland-Bouley K; Franz DN
    Neurology; 2016 Dec; 87(23):2408-2415. PubMed ID: 27815402
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.